budoprutug

Monoclonal antibody

Phase 2topline reported

Evidence outlook

Primary Membranous Nephropathy: topline reported 2026-10-24

The sponsor reported topline results on 2026-10-24 (Initial PrisMN Phase 2 data (interim): mean PLA2R antibody reduction 70% at Week 12; 5 of 13 in immunologic remission). The announcement is listed under Regulatory events.

Also in development:Systemic Lupus Erythematosus · Phase 1/2

Source for the program status

Company guidance: data expected in 2027 (NCT07096843; Climb Bio, Inc., 5 Nov 2026). “Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027” Source ↗

Company guidance: data expected in 2027 (Climb Bio, Inc., 5 Nov 2026). “Budoprutug SC: Future Direction Data in NHPs and healthy volunteers support continued development of SC formulation, with plans to advance to a study in patients to confirm dose and regimen with initial data expected in 2027 NHPs = nonhuman primates, PD = pharmacodynamic, SC = subcutaneous Next Steps Non-Human Primates Data confirmed bioavailability and favorable safety/tolerability Evaluation of SC formulation at full B-cell depleting dose regimen in patients with autoimmune diseases Healthy Volunteers (low dose) Robust PD effects support continued clinical development” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Primary Membranous Nephropathy
Phase 1/2 (3)
Systemic Lupus Erythematosus
NCT06570434 · Tenet Medicines
2025-01 – 2027-04 · Systemic Lupus Erythematosus, SLE, B Cells
What this study did
Other / comorbidity
NCT07043946 · Climb Bio, Inc.
2025-06-30 – 2028-08 · Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19
What this study did
Phase 1 (2)
Systemic Lupus Erythematosus
Other / comorbidity
NCT07090655 · Climb Bio, Inc.
2025-08-11 – 2026-04-07 · Healthy Volunteers
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for Systemic Lupus Erythematosus: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Budoprutug: this drugPhase 1/2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
AnifrolumabApprovedMonoclonal antibodyType I interferon receptor subunit 1 (IFNAR1)Partial signal
NCT04931563: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138
NCT02446899: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%)
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Weak signal
NCT00410384: SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889).
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LitifilimabPhase 3Monoclonal antibodyBDCA2 (CLEC4C), BDCA2 / CD303 (blood dendritic cell antigen 2)Reliable signal
NCT02847598: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3)
Obinutuzumab Beta (Bejescin)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)Phase 3Small moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signalNo reviewed efficacy summary in this indication
AfimetoranPhase 2Small moleculeTLR7/8not yet gradedNo reviewed efficacy summary in this indication
BI 3000202Phase 2Small moleculecGAS (cyclic GMP-AMP synthase)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
EnvudeucitinibPhase 2Small moleculeTYK2Partial signal
NCT05966480: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). missed
FrexalimabPhase 2Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
FT819Phase 2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
ICG318Phase 2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
InebilizumabPhase 2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ObexelimabPhase 2Monoclonal antibodyCD19 / FcγRIIbPartial signal
NCT02725515: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 (Day 225): XmAb5871 21/50 vs Placebo 12/42 missed
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
SanritatugPhase 2Monoclonal antibodyCD38Weak signalNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
VENT-03Phase 2Small moleculecGAS (cyclic GMP-AMP synthase)not yet gradedNo reviewed efficacy summary in this indication
Zolacabtagene AutoleucelPhase 2Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
Aritinercept
Phase 1/2(overall)
Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-TPhase 1/2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
DS-7011aPhase 1/2Monoclonal antibodyToll-like receptor 7 (TLR7) (inhibitor)Weak signal
NCT05638802: Treatment-emergent adverse events: 11/19 DS-7011a participants vs 4/6 placebo participants.
LisaftoclaxPhase 1/2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
ANX009Phase 1Antibody fragmentC1qnot yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
BCD-256Phase 1Monoclonal antibodyBDCA2 (CLEC4C)not yet gradedNo reviewed efficacy summary in this indication
BCMA-CD19 Compound CAR (cCAR) T CellsPhase 1Cell therapyBCMA / CD19Weak signal
NCT05474885: All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months.
BZE2204Phase 1Cell therapyCD19, CD22, and BCMA (tri-antigen)not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 1Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CizutamigPhase 1Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 1Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
F01Phase 1Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
GSK4527363Phase 1——not yet gradedNo reviewed efficacy summary in this indication
GSK5926371Phase 1Biologic (subtype unspecified)CD19 / CD20 (dual-antigen) with CD3 T-cell engagementnot yet gradedNo reviewed efficacy summary in this indication
HC022Phase 1——Weak signalNo reviewed efficacy summary in this indication
IC19 CAR-TPhase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
LBL-047Phase 1Protein / enzyme therapeuticBDCA2 (CLEC4C) / TACInot yet gradedNo reviewed efficacy summary in this indication
NIM-1324
Phase 1(overall)
Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PIT565Phase 1Multispecific antibodyCD19 x CD2 x CD3not yet gradedNo reviewed efficacy summary in this indication
SAR448501Phase 1Multispecific antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
UTAA09Phase 1Cell therapyCD19Weak signalNo reviewed efficacy summary in this indication
UTAA91Phase 1Cell therapyCD19 (B cells) and PD-1+ pathogenic T cellsnot yet gradedNo reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
ZM001Phase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene GeleucelPhase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
GRI-0803
—(overall)
Small moleculeType 2 NKT cells (activator)not yet gradedNo reviewed efficacy summary in this indication
AB-101 (AlloNK)DiscontinuedCell therapyCell therapynot yet gradedNo reviewed efficacy summary in this indication
CadefrecitinibDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
GLPG3970DiscontinuedSmall moleculeSIK2/3not yet gradedNo reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
SolcitinibDiscontinuedSmall moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
Vispacabtagene RegedleucelDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow budoprutug to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
April 2027 (1)
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-04 · NCT07011043 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1/2Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19Recruiting
Est. primary completion 2027-08 · NCT07043946 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-09 · NCT07564596 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Primary Membranous NephropathyRecruiting
Est. primary completion 2027-10 · NCT07096843 · CT.gov ↗

Company guidance: data expected in 2027 (Climb Bio, Inc., 5 Nov 2026). “Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027” Source ↗

What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 October 2026Topline resultInitial PrisMN Phase 2 data (interim): mean PLA2R antibody reduction 70% at Week 12; 5 of 13 in immunologic remission
US · Climb Bio, Inc. · Source ↗
5 May 2026Topline resultPhase 1 topline of subcutaneous budoprutug in healthy volunteers
Climb Bio, Inc. · Source ↗